Welcome to our dedicated page for Royalty Pharma Plc SEC filings (Ticker: RPRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
RPRX鈥檚 reports aren鈥檛 typical income-statement reads鈥攈undreds of royalty streams, milestone receivables, and fair-value marks can make even seasoned analysts pause. If you have ever typed 鈥淩oyalty Pharma SEC filings explained simply鈥� after skimming footnote thirty-two, you know the challenge.
Stock Titan delivers every disclosure the moment it hits EDGAR, then our AI translates legal jargon into plain English. Need a Royalty Pharma annual report 10-K simplified or a Royalty Pharma quarterly earnings report 10-Q filing broken down by therapy class? Prefer the latest Royalty Pharma 8-K material events explained before markets open? Our platform does that, while Royalty Pharma Form 4 insider transactions real-time alert you to executive moves. Common investor questions鈥斺�淗ow are milestone payments recognised?鈥� or 鈥淲here is oncology exposure trending?鈥濃�攁re answered in seconds.
- Track Royalty Pharma insider trading Form 4 transactions and Royalty Pharma executive stock transactions Form 4 side-by-side with price charts.
- Compare cash-flow shifts through each Royalty Pharma earnings report filing analysis, complete with AI-generated visuals.
- Dive into the proxy statement executive compensation details without paging through appendices.
Because Royalty Pharma鈥檚 value hinges on future drug sales, subtle changes in royalty amortisation schedules or credit covenants matter. Our AI spots those lines, highlights risks, and helps in understanding Royalty Pharma SEC documents with AI鈥攂efore the market reacts. Spend less time hunting PDFs, more time acting on insights.
Royalty Pharma plc (RPRX) 鈥� SEC Form 4 filing discloses that new board member Elizabeth H. Weatherman received two equity grants on 31 Jul 2025.
- Initial grant: 2,752 Class A ordinary share RSUs under the 2020 Independent Director Equity Incentive Plan.
- Pro-rated annual grant: 5,806 Class A ordinary share RSUs under the same plan.
Both RSU tranches carry a $0 purchase price and are scheduled to vest 100 % on the earlier of (i) one-year anniversary of grant or (ii) the first subsequent annual shareholder meeting, subject to plan terms.
Following the grants, Weatherman鈥檚 beneficial ownership rises to 8,558 Class A shares, all held directly. No derivative securities were reported.
The filing reflects routine director compensation rather than an open-market purchase; therefore it does not inject fresh cash into the company, nor does it immediately alter share count materially. Nonetheless, the equity-based award modestly aligns the new director鈥檚 incentives with shareholders.
Royalty Pharma plc (RPRX) 鈥� Form 4 insider transaction:
On 31 Jul 2025, director Carole Ho reported receiving 8,558 Class A ordinary shares through two restricted-stock-unit (RSU) grants issued under the 2020 Independent Director Equity Incentive Plan:
- 2,752 RSUs as an initial equity award.
- 5,806 RSUs as a pro-rated annual award.
Both tranches vest 100 % on the earlier of (i) one year from grant or (ii) the next annual shareholders鈥� meeting. The awards carry a cost basis of $0, reflect routine board compensation, and increase Ho鈥檚 direct ownership to 8,558 shares. No shares were sold, no derivatives were involved, and the filing references no Rule 10b5-1 trading plan. The disclosure is informational and does not affect Royalty Pharma鈥檚 fundamentals.
FAQ
What is the current stock price of Royalty Pharma Plc (RPRX)?
What is the market cap of Royalty Pharma Plc (RPRX)?
